Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.

MLA

Gonzalez-Peralta, Regino P., et al. “Elbasvir/Grazoprevir in Children Aged 3-18 Years with Chronic HCV Genotype 1 or 4 Infection: A Pharmacokinetic Modeling Study.” Hepatology Communications, vol. 7, no. 3, Mar. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1097/HC9.0000000000000031.

APA

Gonzalez-Peralta, R. P., Wirth, S., Squires, R. H., Mutschler, F., Lang, T., Pawlowska, M., Sluzewski, W., Majda-Stanislawska, E., Fischler, B., Balistreri, W. F., Jonas, M. M., Blondet, N., Rosenthal, P., Alkhouri, N., Romero, R., Grandhi, A., Castronuovo, P., Caro, L., Lihong Du, & Rosenbloom, D. I. S. (2023). Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study. Hepatology Communications, 7(3), 1–11. https://doi.org/10.1097/HC9.0000000000000031

Chicago

Gonzalez-Peralta, Regino P., Stefan Wirth, Robert H. Squires, Frauke Mutschler, Thomas Lang, Malgorzata Pawlowska, Wojciech Sluzewski, et al. 2023. “Elbasvir/Grazoprevir in Children Aged 3-18 Years with Chronic HCV Genotype 1 or 4 Infection: A Pharmacokinetic Modeling Study.” Hepatology Communications 7 (3): 1–11. doi:10.1097/HC9.0000000000000031.